Analyst Price Target is $20.00
▲ +261.01% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Milestone Pharmaceuticals in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 261.01% upside from the last price of $5.54.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Milestone Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in MontrÃ©al, Canada.